From L-R: AstraZeneca CEO Pascal Soriot, CFO Aradhana Sarin and Alexion CEO Marc Dunoyer presenting Q4 results (Reynald Castañeda for Endpoints News)

Up­dat­ed: ‘Ruth­less’ pipeline pri­or­i­ti­za­tion, obe­si­ty and Chi­na: Three take­aways from As­traZeneca’s Q4 

LON­DON — As­traZeneca on Thurs­day morn­ing teased its vi­sion on how it could po­ten­tial­ly en­ter the obe­si­ty mar­ket, as well as its views on fur­ther Chi­na-based deals. The gi­ant phar­ma al­so un­veiled five pipeline cuts across its meta­bol­ic, rare dis­ease and on­col­o­gy port­fo­lios.

“We have had to re­al­ly ruth­less­ly pri­or­i­tize our R&D projects” to fo­cus on “the most promis­ing op­por­tu­ni­ties,” CEO Pas­cal So­ri­ot said dur­ing an in-per­son press event in Lon­don for its fourth-quar­ter earn­ings.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.